Table 2. Toxicities during treatment.
| Toxicity | R-MPL (N=69) | R-MP (N=38) | All (N=107) |
|---|---|---|---|
| Leukopenia | |||
| Grade 1 | 3 (4.4) | 7 (19.4) | 10 (9.6) |
| Grade 2 | 12 (17.6) | 8 (22.2) | 20 (19.2) |
| Grade 3 | 32 (47.1) | 12 (33.3) | 44 (42.3) |
| Grade 4 | 13 (19.1) | 2 (5.6) | 15 (14.4) |
| Anaemia | |||
| Grade 1 | 6 (8.8) | 6 (16.7) | 12 (11.5) |
| Grade 2 | 31 (45.6) | 20 (55.6) | 51 (49.0) |
| Grade 3 | 27 (39.7) | 6 (16.7) | 33 (31.7) |
| Grade 4 | 2 (2.9) | 0 (0) | 2 (1.9) |
| Thrombocytopenia | |||
| Grade 1 | 11 (16.2) | 10 (27.8) | 21 (20.2) |
| Grade 2 | 11 (16.2) | 2 (5.6) | 13 (12.5) |
| Grade 3 | 20 (29.4) | 0 (0) | 20 (19.2) |
| Grade 4 | 9 (13.2) | 2 (5.6) | 11 (10.6) |
| Infections | |||
| Grade 1 | 2 (2.9) | 3 (8.3) | 5 (4.8) |
| Grade 2 | 12 (17.6) | 8 (22.2) | 20 (19.2) |
| Grade 3 | 24 (35.3) | 8 (22.2) | 32 (30.8) |
| Grade 4 | 3 (4.4) | 0 (0) | 3 (2.9) |
| Transaminases | |||
| Grade 1 | 27 (40.3) | 7 (19.4) | 34 (33.0) |
| Grade 2 | 13 (19.4) | 11 (30.6) | 24 (23.3) |
| Grade 3 | 14 (20.9) | 10 (27.8) | 24 (23.3) |
| Grade 4 | 3 (4.5) | 0 (0) | 3 (2.9) |
| Hyperbilirubinaemia | |||
| Grade 1 | 13 (19.1) | 5 (13.9) | 18 (17.3) |
| Grade 2 | 2 (2.9) | 0 (0) | 2 (1.9) |
| Grade 3 | 0 (0) | 0 (0) | 0 (0) |
| Grade 4 | 0 (0) | 0 (0) | 0 (0) |
| Renal impairment (serum creatinine) | |||
| Grade 1 | 20 (29.4) | 11 (30.6) | 31 (29.8) |
| Grade 2 | 14 (20.6) | 7 (19.4) | 21 (20.2) |
| Grade 3 | 5 (7.4) | 1 (2.8) | 6 (5.8) |
| Grade 4 | 0 (0) | 0 (0) | 0 (0) |
| Mucositis | |||
| Grade 1 | 11 (16.4) | 4 (11.1) | 15 (14.6) |
| Grade 2 | 10 (14.9) | 4 (11.1) | 14 (13.6) |
| Grade 3 | 5 (7.5) | 3 (8.3) | 8 (7.8) |
| Grade 4 | 0 (0) | 0 | 0 (0) |
| Toxic deaths | 7 (10.1) | 2 (5.3) | 9 (8.4) |
Abbreviations: R-MP, rituximab, methotrexate and procarbazine; R-MPL, rituximab, methotrexate, procarbazine and lomustine.
Numbers are frequencies (proportions).